Annotated Medicine and Device Lists
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 10.2. Medicines affecting coagulation |
This medicine has the best evidence for effectiveness and safety. |
| Trinidad and Tobago. Pharmaceutical Ven Listing 2019. Ministry of Health. | Anticoagulants Oral | No observations |
| Jamaica. List of Vital Essential and Necessary Drugs and Medical Sundries for Public Health Institutions. 2015 | 01.03 ANTI-COAGULANT AND ANTIPLATELET DRUGS | No observations |
| Mexico. Cuadro Basico de Medicamentos - 2017 | 10. HEMATOLOGIA | No observations |
| Barbados. Barbados National Drug Formulary (BNDF) | 20.12.04.12. Direct Thrombin Inhibitors | No observations |
| Bahamas. Drug Formulary | 02. CARDIOVASCULAR DRUGS | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 10.2. Medicines affecting coagulation |
This medicine has the best evidence for effectiveness and safety. |
| Trinidad and Tobago. Pharmaceutical Ven Listing 2019. Ministry of Health. | Anticoagulants Oral | No observations |
| Jamaica. List of Vital Essential and Necessary Drugs and Medical Sundries for Public Health Institutions. 2015 | 01.03 ANTI-COAGULANT AND ANTIPLATELET DRUGS | No observations |
| Mexico. Cuadro Basico de Medicamentos - 2017 | 10. HEMATOLOGIA | No observations |
| Barbados. Barbados National Drug Formulary (BNDF) | 20.12.04.12. Direct Thrombin Inhibitors | No observations |
| Bahamas. Drug Formulary | 02. CARDIOVASCULAR DRUGS | No observations |
| List | Section | Observation |
|---|---|---|
| Jamaica. List of Vital Essential and Necessary Drugs and Medical Sundries for Public Health Institutions. 2015 | 01.03 ANTI-COAGULANT AND ANTIPLATELET DRUGS | No observations |
| Mexico. Cuadro Basico de Medicamentos - 2017 | 10. HEMATOLOGIA |
Others observations: etexilato |
| Barbados. Barbados National Drug Formulary (BNDF) | 20.12.04.12. Direct Thrombin Inhibitors | No observations |
| Bahamas. Drug Formulary | 02. CARDIOVASCULAR DRUGS | No observations |